Visor de contenido web Visor de contenido web


1. Aristegui Fernandez J, Diez-Domingo J, Mares Bermudez J, Martinon Torres F. [Vaccination against hepatitis B. Impact of vaccination programmes after 20 years of use in Spain. Is it time for a change?]. Enferm Infecc Microbiol Clin. 2015;33(2):113-8.
2. Breva LP, Domingo JD, Martinez Beneito MA, Barbera JP. Vaccine coverage estimation using a computerized vaccination registry with potential underreporting and a seroprevalence study. Vaccine. 2015;33(18):2183-8.
3. Caballero-Perez P, Tuells J, Rementeria J, Nolasco A, Navarro-Lopez V, Aristegui J. [Acceptability of the HPV vaccine among Spanish university students in the pre-vaccine era: a cross-sectional study]. Rev Esp Quimioter. 2015;28(1):21-8.
4. Diez-Domingo J, Baldo JM, Planelles-Catarino MV, Garces-Sanchez M, Ubeda I, Jubert-Rosich A, et al. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. Influenza Other Respir Viruses. 2015;9(2):68-77.
6. Garces-Sanchez M, Renales-Toboso M, Boveda-Garcia M, Diez-Domingo J. [Measles, mumps, and rubella vaccine. Resurgence of measles in Europe]. Enferm Infecc Microbiol Clin. 2015;33(10):673-8.
7. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-96.
8. Navarro-Illana P, Caballero P, Tuells J, Puig-Barbera J, Diez-Domingo J. [Acceptability of human papillomavirus vaccine in mothers from Valencia (Spain)]. An Pediatr (Barc). 2015;83(5):318-27.
9. Perez-Vilar S, Diez-Domingo J, Lopez-Lacort M, Martinez-Ubeda S, Martinez-Beneito MA. Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain. BMC Infect Dis. 2015;15(1):811.
10. Perez-Vilar S, Diez-Domingo J, Puig-Barbera J, Gil-Prieto R, Romio S. Intussusception following rotavirus vaccination in the Valencia Region, Spain. Hum Vaccin Immunother. 2015;11(7):1848-52.
11. Puig-Barbera J, Mira-Iglesias A, Tortajada-Girbes M, Lopez-Labrador F, Belenguer-Varea A, Carballido-Fernandez M, et al. Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results. Euro Surveill. 2015;20(8).
12. Puig-Barbera J, Tormos A, Trushakova S, Sominina A, Pisareva M, Ciblak MA, et al. The Global Influenza Hospital Surveillance Network (GIHSN): A new platform to describe the epidemiology of severe influenza. Influenza Other Respir Viruses. 2015.
13. Rondy M, Launay O, Puig-Barbera J, Gefenaite G, Castilla J, de Gaetano Donati K, et al. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveill. 2015;20(2).
14. Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, et al. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil(R) in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015;34(9):992-8.
15. Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark C-E, Beeslaar J, et al. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. J Pediatric Infect Dis Soc. 2015.